Decoding vesicle-based precision oncology in gliomas.
Decoding vesicle-based precision oncology in gliomas.
复制标题
DOI：
10.1093/noajnl/vdac035
复制
发表时间：
2022-11
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
细胞外囊泡（EVs）是液体活检中一种有价值的工具，在胶质瘤的诊断、预后和治疗监测方面具有巨大的临床潜力。与组织活检相比，基于ev的液体活检是一种低成本、微创的方法，可以在治疗前、治疗中和治疗后提供肿瘤动态信息。在生物体液中循环的肿瘤源性ev携带复杂的分子生物标志物，包括DNA、RNA和蛋白质，这些标志物可以指示肿瘤的生长和进展。在这里，我们简要回顾了目前用于分离、定量和生化表征胶质瘤患者血浆EV的商业和非商业方法，涉及整个EV分析、突变检测技术以及基因组和蛋白质组学分析。我们回顾了血浆EV分离和分析方法的显著优点和缺点，最后讨论了未来实施EV液体活检治疗胶质瘤的临床转化机会和关键挑战。
Extracellular vesicles (EVs) represent a valuable tool in liquid biopsy with tremendous clinical potential in diagnosis, prognosis, and therapeutic monitoring of gliomas. Compared to tissue biopsy, EV-based liquid biopsy is a low-cost, minimally invasive method that can provide information on tumor dynamics before, during, and after treatment. Tumor-derived EVs circulating in biofluids carry a complex cargo of molecular biomarkers, including DNA, RNA, and proteins, which can be indicative of tumor growth and progression. Here, we briefly review current commercial and noncommercial methods for the isolation, quantification, and biochemical characterization of plasma EVs from patients with glioma, touching on whole EV analysis, mutation detection techniques, and genomic and proteomic profiling. We review notable advantages and disadvantages of plasma EV isolation and analytical methods, and we conclude with a discussion on clinical translational opportunities and key challenges associated with the future implementation of EV-based liquid biopsy for glioma treatment.